Neuroblastoma (NB) is the most common extracranial solid tumor in pediatric patients. Treatment for high-risk patients includes surgery and high dose chemotherapy with autologous stem cell rescue. However, in spite of aggressive therapy, up to 80% of patients relapse and die of disseminated disease. Therefore, novel approaches to the treatment of NB are necessary. One potential approach is viral-directed enzyme prodrug therapy (VDEPT), using adenoviruses to deliver cDNAs encoding carboxylesterases (CEs) that efficiently activate the prodrug CPT-11. This drug has shown encouraging activity in NB patients, but is activated inefficiently in vivo. Work during the previous funding cycle documented that rabbit liver CE/CPT-11 VDEPT sensitizes primary NB cells to CPT-11, and can be used to purge NB cells from human hematopoietic """"""""stem"""""""" cells without toxicity to progenitor cells or CD34+ NOD/SCID repopulating cells. In the next funding cycle, we propose to complete an ongoing nontherapeutic clinical trial for purging bone marrow specimens containing >1% tumor cells, and to identify appropriate CEs to make CE/CPT-11 VDEPT useful for in vivo application.
Specific Aims i nclude: 1) completion of the ongoing clinical trial; 2) modification of a human enzyme to produce an efficient CPT-11 activating enzyme with minimal immunogenicity; and 3) to achieve tumor-specific toxicity in mouse models of NB by using tumor specific promoters and replication-selective adenoviral vectors to deliver CE cDNA. Overall, these studies should provide alternative treatment modalities for high-risk neuroblastoma.
Wierdl, Monika; Tsurkan, Lyudmila; Hatfield, M Jason et al. (2016) Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer. Br J Pharmacol 173:2811-8 |
Hatfield, M J; Tsurkan, L; Hyatt, J L et al. (2010) Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin. Br J Pharmacol 160:1916-28 |
Hatfield, Jason M; Wierdl, Monika; Wadkins, Randy M et al. (2008) Modifications of human carboxylesterase for improved prodrug activation. Expert Opin Drug Metab Toxicol 4:1153-65 |
Barthel, Benjamin L; Torres, Renee C; Hyatt, Janice L et al. (2008) Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug. J Med Chem 51:298-304 |
Aboody, K S; Najbauer, J; Danks, M K (2008) Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15:739-52 |
Wierdl, M; Tsurkan, L; Hyatt, J L et al. (2008) An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther 15:183-92 |
Streit, Timothy M; Borazjani, Abdolsamad; Lentz, Shellaine E et al. (2008) Evaluation of the 'side door'in carboxylesterase-mediated catalysis and inhibition. Biol Chem 389:149-62 |
Wadkins, Randy M; Hyatt, Janice L; Edwards, Carol C et al. (2007) Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds. Mol Pharmacol 71:713-23 |
Hicks, Latorya D; Hyatt, Janice L; Moak, Teri et al. (2007) Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem 15:3801-17 |
Hyatt, Janice L; Moak, Teri; Hatfield, M Jason et al. (2007) Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem 50:1876-85 |
Showing the most recent 10 out of 34 publications